Study Summary
The objectives are to assess the safety and tolerability of 6 vaccine doses of MVX-ONCO-1, administered sub-cutaneously (injections and capsules implantations), in patients with advanced metastatic solid tumor in progression who are not or not any longer amenable to any standard therapy of their tumour disease.
Want to learn more about this trial?
Request More InfoInterventions
TreatmentOTHER
Treatment is the implantation of loaded capsules + injection of irradiated autologous tumor cells
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Hopitaux Universitaires de Genève - HUG | Geneva | Canton of Geneva | Switzerland |